Together, our in vivo and in vitro data on HDAC4 suggest that it has a protective role against obesity and could therefore represent a potential therapeutic target for management of obesity and presumably in insulin resistance and type 2 diabetes. Here, HDAC4 is linked to type 2 diabetes mellitus.